JPS61113460A - Hollow yarn membrane for purifying blood - Google Patents

Hollow yarn membrane for purifying blood

Info

Publication number
JPS61113460A
JPS61113460A JP23501384A JP23501384A JPS61113460A JP S61113460 A JPS61113460 A JP S61113460A JP 23501384 A JP23501384 A JP 23501384A JP 23501384 A JP23501384 A JP 23501384A JP S61113460 A JPS61113460 A JP S61113460A
Authority
JP
Japan
Prior art keywords
blood
hollow fiber
membrane
weight
spinning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP23501384A
Other languages
Japanese (ja)
Inventor
粟田 僚一
泉 康伸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Bakelite Co Ltd
Original Assignee
Sumitomo Bakelite Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Bakelite Co Ltd filed Critical Sumitomo Bakelite Co Ltd
Priority to JP23501384A priority Critical patent/JPS61113460A/en
Publication of JPS61113460A publication Critical patent/JPS61113460A/en
Pending legal-status Critical Current

Links

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。
(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.

Description

【発明の詳細な説明】 〔産業上の利用分野〕 本発明辻、血液清浄化用中空糸型人工臓器に使用される
中空糸膜に関するものでbる。更に詳しくは、慢性ある
いは急性の腎不全患者の治療金目的として、すぐれた特
性と安定性t”肩する、血液透析または血液−過による
血液清浄化に用いられる中空糸膜に関テるものである。
DETAILED DESCRIPTION OF THE INVENTION [Field of Industrial Application] The present invention relates to a hollow fiber membrane used in a hollow fiber type artificial organ for blood purification. More specifically, it relates to hollow fiber membranes used for hemodialysis or blood purification by hemodialysis, which have excellent properties and stability for the treatment of patients with chronic or acute renal failure. be.

その目的とするところは、濾過特性を特定の範囲内にコ
ントローある。
The objective is to control the filtration characteristics within a specified range.

【従来技術〕[Conventional technology]

現在、慢性腎不全患者の治療法としては、血液ポンプを
使用した間歇的な血液透析や血液−過が一般に行なわれ
ている。一方、手術後の合併症等で生じる急性腎不全患
者の治療に対しては、迅速な水分及び溶質の大量の除去
が必要となってくるため、従来め間歇的治療法では対応
できない。この場合には連続的血液透析ま次は血g、濾
過が効果的でちるが、1日〜2週間程度連続的に使用す
るため、これに使用される膜としては、厳しい性能が要
求され、従来の一般的に用いられている血液透析膜や血
液濾過膜では血液適、合性に問題が6を大膜内で凝血が
起こるなど連続的使用は困難であった。
Currently, intermittent hemodialysis or hemodialysis using a blood pump is generally performed as a treatment for patients with chronic renal failure. On the other hand, for the treatment of patients with acute renal failure caused by complications after surgery, etc., it is necessary to quickly remove large amounts of water and solutes, and thus conventional intermittent treatment methods cannot be used. In this case, continuous hemodialysis and filtration are effective, but since they are used continuously for about 1 day to 2 weeks, the membrane used for this requires strict performance. Conventional commonly used hemodialysis membranes and hemofiltration membranes have problems in blood compatibility and compatibility, and blood clots occur within the large membrane, making continuous use difficult.

更に、長時間の連続使用では患者の心臓に大きな負担が
かかる血液ポンプの使用は好ましくな(、患者自身の血
圧のみに、よって体外循環を行う治療法も検討されてS
す、この場合患者の血圧に応じた血流変動、荷に血流低
下により1内に血栓が生じ易いことから、従来の膜の使
用は不可能であった。
Furthermore, it is not recommended to use a blood pump, which puts a heavy burden on the patient's heart if used continuously for a long time.
In this case, it was impossible to use conventional membranes because blood flow fluctuates depending on the patient's blood pressure and blood flow decreases, which tends to cause thrombi to form within the tube.

!   〔発明の目的〕 本発萌者らは、以上のような長時間の連続的血液透析ま
たは血液濾過により、血液の清浄化を安定して行うこと
がでさる中空糸膜を得んとして鋭意研究を進めた結果、
ポリスルホン系樹脂からなり時定の範囲の一過時性ft
有する中空糸膜が極めてすぐれた性能′t−有すること
を見出し、更にこの知見に基づき種々の検討を行った結
果本発明を完成するに至つ九ものである。
! [Purpose of the Invention] The present inventors have conducted extensive research in an effort to obtain a hollow fiber membrane that can stably purify blood through long-term continuous hemodialysis or hemofiltration as described above. As a result of proceeding with
Made of polysulfone resin, transient ft with a fixed time range
It was discovered that the hollow fiber membrane of the present invention has extremely excellent performance, and based on this knowledge, various studies were carried out, resulting in the completion of the present invention.

〔発明の構成〕[Structure of the invention]

すなわち本発明は、ポリスルホン系1)i脂からなり、
水の透過率が500− wooOml/wH1i一時間
am’の範囲内にあり、且つ重量平均分子量65000
〜75000であるデキストランの阻止率が80〜70
%の範囲内にあること@:q!!徴とする血液清浄化用
中空糸膜である。
That is, the present invention consists of polysulfone-based 1) i-fat,
The water permeability is within the range of 500-wooOml/wH1i 1 hour am', and the weight average molecular weight is 65,000.
The inhibition rate of dextran is ~75,000 and is 80-70
Must be within the range of %@:q! ! This is a hollow fiber membrane for blood purification.

ここで用語の説明を行うと、以下の通りである。Here, the terms will be explained as follows.

濾過率(水の透過率1 (ゴ/顛Hぴ・時間・ゴ] 一過した液の量(llIjJ p過圧tmH,FJx濾過時間(時間]×有効膜面積帷
)   1阻止率 (%J ないものであるが、便宜的に到定開t!j15〜10分
後Q値を取るのが適当である。、、末た、デキストラン
の阻止率は、0.2重量%のでダスト2ンを含む□゛ 
水溶液、を中空糸内に8ける線42〜20cm/秒で1
〒 循環せしめ、循環開始5分後9F液及び循環液のデキス
トラン濃度より算出した。、以下実施例及び比較例を含
め同様な測定条件とした。
Filtration rate (Water permeability 1 (Go/Hpi・Time・Go) Amount of passed-through liquid (llIjJ p Overpressure tmH, FJ x Filtration time (hours) x Effective membrane area) 1 Rejection rate (%J However, for convenience, it is appropriate to take the Q value 15 to 10 minutes after the final opening time.Furthermore, the rejection rate of dextran is 0.2% by weight, so the dust Including □゛
aqueous solution, into the hollow fiber at a rate of 42 to 20 cm/sec.
Calculated from the dextran concentration of the 9F solution and the circulating fluid 5 minutes after the start of circulation. Similar measurement conditions were used in the following Examples and Comparative Examples.

更に詳細に本発明の説明上行う、と、ポリスルホン、系
樹脂よりなる中空糸膜は、ポリスルホン系樹脂、該樹j
h老溶解し得る極性を機溶剤及び龜加型t−溶解せしめ
て紡糸原液とし、湿式陣により中空糸膜′J&:紡糸し
た後、更に適当な処理′を行ない所定の濾過時性を付与
せしめ石ものである。
To explain the present invention in more detail, the hollow fiber membrane made of polysulfone-based resin is made of polysulfone-based resin, the resin
The soluble polarity is dissolved in a mechanical solvent and added to form a spinning dope, which is spun into a hollow fiber membrane using a wet process, and then subjected to further appropriate treatment to impart a predetermined filtration property. It is made of stone.

ここで、ポリスルホン系樹脂と1は o@造ヲ、肩す6もO”″6Bo紡糸原a、l:l12
 OM リ’、t。
Here, polysulfone resin and 1 are o @ construction, shoulder 6 is also O""6Bo spinning raw material a, l: l12
OM li', t.

〜ホン予樹脂の一度はlO〜25重瀘チ1.竺ましくは
12〜zOt量チとするのか望ましし)。ポリスルホン
系横力旨を溶解する極性有機浴剤としてはジメチルホル
ムアミド、N−メチル−2−′ピロリドン等が用いられ
るが、ポリスルホン系a脂e’rW゛解するものであれ
ばこれらに限定されない。
~ Once the resin is 10 ~ 25 layers 1. In general, it is desirable to set the amount to 12 to zOt). Dimethylformamide, N-methyl-2-'pyrrolidone, and the like are used as polar organic bath agents for dissolving polysulfone-based lateral forces, but are not limited to these as long as they can dissolve polysulfone-based a-liquids.

添加剤としては、金属塩ま九はポリスルホン系樹脂の非
俗剤が挙げられる。金属塩の例としては1価または21
)ffJの陽イオン金属塩、すなわちLlcl、LtB
r %NaC1、NaBr %KC1,KBr 、 M
gClxMgBr2、Ca(J2、CaBr1等が挙げ
られるがこrらに限定されない。ポリスルホン系樹脂の
非躬剤としては、ケトン系、エーテル系、フラン系、肩
機戚系、有機酸無水物系、有機酸エステル系、界面活性
剤等が挙げられるがこれらに限定されない。更に金属塩
と非溶剤を組合わせ、また、2種以上の非浴剤七組合わ
せることも可能である。
Examples of additives include metal salts and non-vulgar agents of polysulfone resins. Examples of metal salts are monovalent or 21
) ffJ cationic metal salts, namely Llcl, LtB
r %NaC1, NaBr %KC1, KBr, M
Examples include, but are not limited to, gClxMgBr2, Ca(J2, CaBr1, etc.). Antioxidants for polysulfone resins include ketones, ethers, furans, organic compounds, organic acid anhydrides, and organic Examples include, but are not limited to, acid esters, surfactants, etc. Furthermore, it is also possible to combine a metal salt and a non-solvent, or to combine seven combinations of two or more types of non-bath agents.

紡糸原液は上記の各成分を混合し、室温から100°C
程度に加温しながら攪拌溶解して得られる。
The spinning stock solution is made by mixing the above components and heating it at room temperature to 100°C.
It is obtained by stirring and dissolving while heating to a certain degree.

次いで、2重管構造の中空繊維製造用ノズルを用い、外
側の環状口から紡糸原at″、芯部から凝固at凝固浴
中へ吐出し凝固せしめる湿式紡糸法によって中空糸膜を
得る。
Next, a hollow fiber membrane is obtained by a wet spinning method using a hollow fiber manufacturing nozzle having a double tube structure and discharging the spinning material from the outer annular opening into the spinning material at" and the core into the coagulation bath.

ノズル芯部より吐出し紡糸原液の内部より凝固せしめる
内部凝固液、及び外部より凝固せしめる凝固浴の組成は
、操作性の点からは水単独であることが望ましいが、水
に金属塩及び/ま九はポリスルホン系樹脂の溶剤、及び
/またはポリスルホン系樹脂の非溶剤を加えることによ
り、分離膜の中間層の構造t−変化させることが可能で
ある。こ’   、ニー1:1).i!ilKKffi
mL、、*;Ez4!dAtli+−!、 LiCff
f、 L8,8.。
The composition of the internal coagulating liquid discharged from the nozzle core and coagulating from the inside of the spinning stock solution and the coagulating bath coagulating from the outside is preferably water alone from the viewpoint of operability. Ninth, by adding a polysulfone resin solvent and/or a polysulfone resin non-solvent, it is possible to change the structure of the intermediate layer of the separation membrane. K', Ni 1:1). i! ilKKffi
mL,,*;Ez4! dAtli+-! , LiCff
f, L8,8. .

NaCl−NaBr %KC1s KBr −MgCl
5、MgBr5、CaCA!2、CaBr、 7Zどが
挙げられるが、これらに限定されず、また2穏以上の金
属塩の組合わせも可能である。また、凝固浴に添加し得
るポリスルホン系樹脂の溶剤は、ジメチルホルムアミド
、N−メチル−2−ピロリドンなどであるがこれらに限
定されず、また2種以上の溶剤の組合わせも可能である
。凝固浴に添加し得るポリスルホン系樹脂の非溶剤は、
アルコール系、ケトン系などがめるがこれらに限定され
ず、ま六2種以上の非溶剤の組み合わせも可能である。
NaCl-NaBr %KC1s KBr-MgCl
5, MgBr5, CaCA! Examples include, but are not limited to, 2, CaBr, 7Z, etc., and a combination of two or more metal salts is also possible. Further, solvents for polysulfone resins that can be added to the coagulation bath include, but are not limited to, dimethylformamide, N-methyl-2-pyrrolidone, etc., and a combination of two or more solvents is also possible. Non-solvents for polysulfone resins that can be added to the coagulation bath are:
Non-solvents include, but are not limited to, alcohol-based and ketone-based solvents, and combinations of 62 or more types of non-solvents are also possible.

中空糸を紡糸する際の吐出条件、すなわち製膜条件とし
て主に温度管理が重要であり通常室温近辺で行うが、紡
糸原液の組成により室温に8いて不安定な場合は加温紡
糸を行い、紡糸温度は室温〜100°0の範囲が適当で
ある。更に得られた膜には水に不溶性の添加剤を含む場
合もあるため・エタノール等に浸漬させ脱醪剤及び脱添
加剤を行°″C@、 7tl″1)′4″j″′”S″
′Ji9gCh;b・92 。。
Temperature control is mainly important when spinning hollow fibers, i.e., film forming conditions, and is usually carried out around room temperature, but if the composition of the spinning stock solution makes it unstable at room temperature, warm spinning is performed. The spinning temperature is suitably in the range of room temperature to 100°0. Furthermore, since the obtained film may contain additives that are insoluble in water, it is immersed in ethanol etc. to de-melt and remove additives. S''
'Ji9gCh;b・92. .

糸膜の性能は、上記の紡糸原液組成、吐出条件及び凝固
液の組成を適宜に組合わせることで自由にコントロール
できる。中空糸膜t−製造した後、ポリスルホン系樹脂
の非溶剤に浸漬し、gO°0以上150℃以下の温度で
熱処理することもMq!!性のコントロールに効果的で
ある。熱処理時間は通常80分〜2時間で十分であるが
、1時間程度が望ましい。
The performance of the yarn membrane can be freely controlled by appropriately combining the above-mentioned spinning dope composition, discharge conditions, and coagulation liquid composition. After producing the hollow fiber membrane, it may be immersed in a non-solvent of polysulfone resin and heat treated at a temperature of gO°0 to 150°C. ! Effective for sexual control. A heat treatment time of 80 minutes to 2 hours is usually sufficient, but about 1 hour is desirable.

ココで、水の透過率が2000 rtil/wiHji
一時間・−以上で、且つ重量平均分子量65000〜7
5000であるデキストランの阻止率がaO*以下であ
れば中空糸膜の内表面上に3ける血球成分及び蛋白質等
による目詰りのため、中空糸内での凝血が起こり易く安
定した血液透析や血液P通が行えなくなる。一方、水の
透過率が500 at/ymH9・時間・は以下で、且
つ重量平均分子量65000〜75000のデキストラ
ンの阻止率が70%以上の場合には、血液の濾過流量が
極端に減少し、効果的な血液透析や血g、濾過が不可能
となる。仮にこのような中空糸膜の装入本数を増やした
としても中空糸内の血流が低下し、その結果血橙が生成
し易くなる。
Here, the water permeability is 2000 rtil/wiHji
1 hour - or more, and weight average molecular weight 65,000 to 7
If the rejection rate of dextran, which is 5000, is less than aO*, the inner surface of the hollow fiber membrane is clogged with blood cell components, proteins, etc., and blood coagulation within the hollow fiber is likely to occur, resulting in stable hemodialysis and blood flow. You will not be able to send P-mails. On the other hand, if the water permeability is less than 500 at/ymH9·hr and the rejection rate of dextran with a weight average molecular weight of 65,000 to 75,000 is 70% or more, the blood filtration flow rate will be extremely reduced and the effectiveness will be reduced. Standard hemodialysis and blood filtration become impossible. Even if the number of such hollow fiber membranes to be loaded is increased, the blood flow within the hollow fibers will decrease, and as a result, blood orange will be more likely to be produced.

〔発明の効果〕〔Effect of the invention〕

本発明のポリスルホン系樹脂よりなる中空糸膜は、水の
透過率及びデキストランの阻止率といった膜性能を適当
な範囲にコントロールすることにより、血液透析または
血液−過を効率よ(且つ安定に行い得るものセある。従
って、慢性あるいは急性腎不全患者の治療に8いて、従
来困難とされていた長時間の連続的血液透析または血液
ヂ過法による血液清浄化のみならず、血液ポンプを使用
しない体外循環法による血g、清浄化に対しても極めて
肩効である。
The hollow fiber membrane made of the polysulfone resin of the present invention can perform hemodialysis or blood filtration efficiently (and stably) by controlling membrane performance such as water permeability and dextran rejection within an appropriate range. Therefore, in the treatment of patients with chronic or acute renal failure, in addition to blood purification using long-term continuous hemodialysis or blood filtration methods, which were previously considered difficult, extracorporeal methods without the use of blood pumps are needed. It is also extremely effective for blood purification through circulation methods.

この他、多臓器不全、薬剤治療抵抗性心不全、洋種等に
対しても連続的血液濾過が効果的であり、このような症
例に長時間安定して使用でさる血液−過器としても好適
である。さらに将来、慢性の腎不全患者に対しても携帯
型人工腎臓や家庭透析等にも使用可能と考えられ、応用
範囲はかなり広いものである。また、現行の血液ポンプ
金使用した間歇的治療に8いても、血液適合性のより優
れた血液透析器や血液ヂ過器を提供することが可能とな
る@ 以下本発明の実施例について説明する。
Continuous hemofiltration is also effective for multiple organ failure, heart failure resistant to drug therapy, and Western species, and it is suitable as a blood filter that can be used stably for long periods of time in such cases. be. Furthermore, in the future, it is thought that it will be possible to use it for patients with chronic renal failure as well as for portable artificial kidneys, home dialysis, etc., and the range of applications is quite wide. In addition, even if the current intermittent treatment using blood pumps is used, it becomes possible to provide hemodialyzers and blood filters with better blood compatibility.Examples of the present invention will be described below. .

実施例1 ポリスルホン(UCC社a%UDEL P−1700)
t−16,5重量%、浴剤としてジメチルホルムアミド
?75.5重量%、添加剤としてメチル−n−ブチルケ
トンを8重量%混合し、80℃で4時間。
Example 1 Polysulfone (UCC a%UDEL P-1700)
t-16.5% by weight, dimethylformamide as a bath agent? 75.5% by weight and 8% by weight of methyl-n-butyl ketone as an additive were mixed at 80°C for 4 hours.

加熱攪拌上行い均一溶液を得た。この紡糸原液を中空繊
維製造用ノズルの外側の環状口から、また厄部からは水
を吐出し、水からなる凝固浴へ導いて凝固せしめ、45
m/分の速度で巻取りt行りた。ここで紡糸温度、すな
わち紡糸原液及び内部凝固液の温度は50℃でるりた。
The mixture was heated and stirred to obtain a homogeneous solution. This spinning dope is discharged from the outer annular opening of the hollow fiber manufacturing nozzle and water is discharged from the troubled part, and is led to a coagulation bath consisting of water and coagulated.
Winding was carried out at a speed of m/min. Here, the spinning temperature, that is, the temperature of the spinning dope and the internal coagulating liquid, was 50°C.

巻取った中空糸水に浸漬し大状態で、1)0℃1時間の
永住で行った。
The wound hollow fiber was immersed in water and left in a large state for 1) permanent residence at 0°C for 1 hour.

得られた膜は内径220μ、膜厚45μであり六。The obtained film had an inner diameter of 220μ and a film thickness of 45μ.

!   阻止率の評価には重量平均分子量約7万のデキ
ストラン(7アルマシアケミ力ルズ社ll、T ? O
jを用い九。水の透過率及びデキストランの阻止率の測
定結果t−第1!5!に示す。
! To evaluate the rejection rate, dextran with a weight average molecular weight of approximately 70,000 (7 Almasia Chemiforces Co., Ltd., T?O
9 using j. Measurement results of water permeability and dextran rejection t-1st!5! Shown below.

血液の透析性能は、1x本88000本、有効長18a
aのモジエールを作成し、体重的10KPの尿管結紮し
たピーグル犬を用い、ポンプ駆動による体外循環を行つ
九。この時の血流量はzoowt7分であり九。透析液
の循環量は5001)J/分で、ヘノ(リンは500I
U/時間の持続注入を行りた。その結果、100時間以
上にわたりて低分子物質の除去及び除水能は安定であり
、終了時の膜内の血栓は殆んど見られなかった。血g、
濾過の場合も透析液以外は同様に行りた結果、100時
間以上にわfI−りて十分な除水能と安定な一過が可能
であう九〇以下の実施例及び比較例に8いては、特に断
らない限り製膜及び性能評価の方法は本冥施例と同様に
行った・ 比較例1 yH!j fis−ytcy (UCC@@、 UDE
L P−170071’k1)重量−1浴刑としてN−
メチル−2−ピロリドンt83.5重量饅、添加剤とし
てメチル−n−ブチルケトンt″5.5重量−混合し、
紡糸IjKfILとした。得られた中空糸膜の水の透過
率及びデキストランの阻止率1i−第工費に示す。
Blood dialysis performance: 1 x 88,000 bottles, effective length 18a
A model was created using a peagle dog weighing 10 KP with ureteral ligation, and extracorporeal circulation was performed using a pump. The blood flow at this time was zoowt 7 minutes, which was 9. The circulation rate of dialysate is 5001) J/min, and the amount of heno(phosphorus) is 500 I
A continuous infusion of U/hour was given. As a result, the ability to remove low molecular weight substances and water removal was stable for over 100 hours, and almost no thrombus was observed within the membrane at the end of the test. blood g,
In the case of filtration, we performed the same procedure except for the dialysate, and found that there were 8 of the 90 or less examples and comparative examples that had sufficient water removal ability and stable filtration for more than 100 hours. Unless otherwise specified, the methods of film formation and performance evaluation were performed in the same manner as in this Example. Comparative Example 1 yH! j fis-ytcy (UCC@@, UDE
L P-170071'k1) Weight-1 N- as punishment
Methyl-2-pyrrolidone t83.5 wt., methyl-n-butylketone t''5.5 wt. as an additive, mixed;
The spun yarn was designated as IjKfIL. The water permeability and dextran rejection rate of the obtained hollow fiber membrane are shown in 1i - 1st construction cost.

血液の透析及び濾過ではいずれも入口圧か徐々に増加し
、除水能も減少傾向で、40〜bO時間で1)!績続行
不能とな−)た。終了時の膜内は血栓が数多く認められ
た。また、血液ポンプを使用せず1 に血液透析及び血
液−過を行ったところ、更に短時間で血栓が生じ、約2
0時間で体外循環不能となつ文。
In both blood dialysis and filtration, the inlet pressure gradually increases, and the water removal capacity also tends to decrease, 1) at 40 to bO hours! It became impossible to continue. Many thrombi were observed within the membrane at the time of completion. In addition, when hemodialysis and blood filtration were performed without using a blood pump, blood clots occurred in an even shorter period of time, and approximately 2
Natsufumi became unable to perform extracorporeal circulation at 0 hours.

比較例2 ポリエーテルスルホン(ICI社展、Victre X
80GP)をlす重量−5溶剤としてN−メチル−2−
ピロリドンt″?6重量%、添加剤としてドデシルベン
ゼンスルホン醗ナトリウム(花王アトラス社裏、ネオベ
レツ、クス0675重量%を混合し、紡糸原液とした。
Comparative Example 2 Polyether sulfone (ICI Exhibition, Victor
N-methyl-2- as solvent
A spinning stock solution was prepared by mixing 6% by weight of pyrrolidone t″ and 675% by weight of sodium dodecylbenzenesulfone (Kao Atlas Co., Ltd., Neoberetsu, Kusu 0675% by weight) as an additive.

得られた中空糸膜の水の透過率及びデキストランの阻止
−t−第1表に示す。
The water permeability and dextran inhibition of the obtained hollow fiber membrane are shown in Table 1.

血液の透析及び−過では血液ポンプの有無によらず比較
的安定であったが、約24FIII間経過後、犬の状態
が悪化し、8う吐など腎不全特有の症状を呈し、約50
−60時間以上の続行は不可能であった。こ九は、除水
能及び血中の低分子物質の除去が不十分なためであると
推定される。
Blood dialysis and treatment were relatively stable regardless of the presence or absence of a blood pump, but after approximately 24 days, the dog's condition worsened and the dog exhibited symptoms characteristic of renal failure, such as vomiting.
- It was impossible to continue for more than 60 hours. This is presumed to be due to insufficient water removal ability and insufficient removal of low molecular weight substances from the blood.

実施例2 ホIJ s−fルスルy%ン(ICI社製、Vtctr
e X800PJを15重誉チ、浴剤としてジメチルホ
ルムアミドを76重量%、添加剤としてプロピルアルコ
ールとラクリルベタイン(花王アトラス社義、アンヒト
ール214B)le組合わせて用いそれぞれ6及びdi
−iチを混合し、紡糸原液とした。紡糸温度40°0、
巻取速度8971!/分、熱処理温度100°0の条件
で得られ次、膜の内径及び膜厚はそれぞれzOOμ、8
5μであった。膜の性能t−第1表に示す。
Example 2 IJ s-f Luslun (manufactured by ICI, Vtctr)
e X800PJ was used in combination with 15% of weight, dimethylformamide was 76% by weight as a bath agent, and propyl alcohol and lacryl betaine (manufactured by Kao Atlas Co., Ltd., Amhitol 214B) were used in combination with 6% and 1% of dimethyl, respectively.
-i was mixed to obtain a spinning stock solution. Spinning temperature 40°0,
Winding speed 8971! /min, heat treatment temperature 100°0, and the inner diameter and thickness of the film were zOOμ and 8, respectively.
It was 5μ. Membrane performance t-shown in Table 1.

血液の透析及び−過では血液ポンプの有無によらず極め
て安定で、100時間以上にわ危って十分な除水能を示
し、犬の状態も良好でありた。
In blood dialysis and dialysis, it was extremely stable regardless of the presence or absence of a blood pump, and showed sufficient water removal ability for more than 100 hours, and the dog was in good condition.

実施例8 ポリスルホン(TJCC社製、UDEL  P−170
0)14重i%、N−メチル−2−ピロリドン 79重
量チ、添加剤としてNaBr  2重量慢及びジグリシ
ジルエーテル53![1t−混合し、紡糸原液を得た。
Example 8 Polysulfone (manufactured by TJCC, UDEL P-170
0) 14% by weight, N-methyl-2-pyrrolidone 79% by weight, NaBr 2% by weight as additives and diglycidyl ether 53%! [It was mixed to obtain a spinning dope.

実施例2と同様にして°製膜し、膜性能を評価したとこ
ろ41表の通りであった。動物実験に8いても極めて安
定な性能を示し、100時間の血液透析及び−過の後に
8いても中空糸内の血橙は殆んど見られなかり大。
A film was formed in the same manner as in Example 2, and the film performance was evaluated as shown in Table 41. It showed extremely stable performance even after 100 hours of hemodialysis in animal experiments, and almost no blood orange was observed within the hollow fibers even after 100 hours of hemodialysis.

Claims (2)

【特許請求の範囲】[Claims] (1)ポリスルホン系樹脂からなり、水の透過率が50
0〜2000ml/mmHg・時間・m^3の範囲内に
あり、且つ重量平均分子量65000〜75000であ
るデキストランの阻止率が30〜70%の範囲内にある
ことを特徴とする血液清浄化用中空糸膜。
(1) Made of polysulfone resin, water permeability is 50
A hollow chamber for blood purification, characterized in that the rejection rate of dextran having a weight average molecular weight of 65,000 to 75,000 is within the range of 30 to 70%, and the rate is within the range of 0 to 2000 ml/mmHg/hour/m^3. Thread membrane.
(2)ポリスルホン系樹脂が ▲数式、化学式、表等があります▼、 ▲数式、化学式、表等があります▼または ▲数式、化学式、表等があります▼ の繰り返し単位を有する重合体より成ることを特徴とす
る、特許請求の範囲第(1)項記載の血液清浄化用中空
糸膜。
(2) Polysulfone resin is composed of a polymer having the following repeating units: A hollow fiber membrane for blood purification according to claim (1).
JP23501384A 1984-11-09 1984-11-09 Hollow yarn membrane for purifying blood Pending JPS61113460A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP23501384A JPS61113460A (en) 1984-11-09 1984-11-09 Hollow yarn membrane for purifying blood

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23501384A JPS61113460A (en) 1984-11-09 1984-11-09 Hollow yarn membrane for purifying blood

Publications (1)

Publication Number Publication Date
JPS61113460A true JPS61113460A (en) 1986-05-31

Family

ID=16979775

Family Applications (1)

Application Number Title Priority Date Filing Date
JP23501384A Pending JPS61113460A (en) 1984-11-09 1984-11-09 Hollow yarn membrane for purifying blood

Country Status (1)

Country Link
JP (1) JPS61113460A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042783A (en) * 1996-03-21 2000-03-28 Kaneka Corporation Hollow yarn membrane used for blood purification and blood purifier

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6042783A (en) * 1996-03-21 2000-03-28 Kaneka Corporation Hollow yarn membrane used for blood purification and blood purifier

Similar Documents

Publication Publication Date Title
JPH0647262A (en) Method for highly efficient removal of low-density lipoprotein from whole blood
US5736046A (en) High-flux hollow-fiber membrane with enhanced transport capability and process for making same
JP2000140589A (en) Porous polysulfone film
WO2000072950A1 (en) Cellulose derivative hollow fiber membrane
JPS61113460A (en) Hollow yarn membrane for purifying blood
JPH0347127B2 (en)
JP2703266B2 (en) Polysulfone hollow fiber membrane and method for producing the same
JPH053335B2 (en)
JPS62221402A (en) Production of hollow fibrous separation membrane
JPS62121608A (en) Method for producing hollow yarn membrane for purifying blood
JPS61113458A (en) Blood purifier
JPH0475765B2 (en)
JPS61293502A (en) Separation film for purifying blood
JP2000210544A (en) Production of semipermeable membrane
JPS60806A (en) Manufacture of plasma albumin permeable hollow yarn membrane
JPH0450850B2 (en)
KR930003740B1 (en) Producing method of polysulfon membrane
JP4381022B2 (en) Hollow fiber blood purification membrane
JP2005074019A (en) Hollow fiber type blood purification membrane
JPS6045358A (en) Serum separating membrane and its preparation
JPS59209611A (en) Hollow yarn like membrane and preparation thereof
JPS6411322B2 (en)
JPH0376975B2 (en)
JPS61103504A (en) Preparation of hollow fibrous separation membrane
JPH0445210B2 (en)